cd31  (Bioss)

Journal: Bioactive Materials

Article Title: Biodegradable Mg 2+ -releasing piezoelectric scaffold for segmental bone defect repair

doi: 10.1016/j.bioactmat.2026.02.017

Figure Lengend Snippet: In vitro evaluation of osteogenic differentiation on Mg 2+ -releasing piezoelectric scaffolds. A) ALP staining of BMSCs cultured with WH Gel and PWH Gel (Scale bar: 1 mm). B) ARS staining of BMSCs cultured with WH Gel and PWH Gel (Scale bar: 1 mm). C-F) RT-qPCR results showing the relative mRNA expression of OPN, RUNX2, OCN, and COL-I in BMSCs cultured with cryogels for 7 days and 14 days. CLSM images showing the expression of (G) OPN, (H) RUNX2, (I) OCN, and (J) COL-I in BMSCs co-cultured with WH Gel and PWH Gel (Scale bar: 50 μm). Data are presented as mean ± S.D. (n = 3 independent replicates). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; NS, not significant.

Article Snippet: Immunohistochemical staining was carried out for COL-I (Proteintech, 28083-1-AP, USA).

Techniques: In Vitro, Staining, Cell Culture, Quantitative RT-PCR, Expressing

Journal: Bioactive Materials

Article Title: Biodegradable Mg 2+ -releasing piezoelectric scaffold for segmental bone defect repair

doi: 10.1016/j.bioactmat.2026.02.017

Figure Lengend Snippet: In vivo assessments of large segmental bone defect regeneration using Mg 2+ -releasing piezoelectric scaffold. A-B) Schematic showing the surgical procedure for scaffold implantation in rat radial defects (Scale bar = 1 cm). C) Macroscopic images of the defect site at 6- and 12- weeks post-implantation. D) RUS scores for radial repair. E) 3D micro-CT images of the defects at 6- and 12- weeks post-implantation (Scale bar = 3 mm). F-G) Quantitative micro-CT analysis of BV/TV and trabecular number (Tb.N) in cryogel-treated regions at 6- and 12- weeks post-implantation. H) Representative H&E and Masson's trichrome staining images of defect tissues at 6- and 12-weeks post-implantation (Scale bar: 1 mm). I) Immunohistochemical staining for COL-I (Scale bar: 1 mm). J) Representative immunofluorescence staining of CD31 (Scale bar: 1 mm). Data are expressed as mean ± S.D. (n = 3 independent replicates). Statistical significance was determined as ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; NS, not significant.

Article Snippet: Immunohistochemical staining was carried out for COL-I (Proteintech, 28083-1-AP, USA).

Techniques: In Vivo, Micro-CT, Staining, Immunohistochemical staining, Immunofluorescence

Journal: Bioactive Materials

Article Title: LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer

doi: 10.1016/j.bioactmat.2025.12.015

Figure Lengend Snippet: Analysis of tumor microenvironment and systemic safety evaluation. (A) Representative immunofluorescence staining of tumor tissues from different treatment groups, showing CD31 + blood vessels (red), CD206 + M2 macrophages (green), and DAPI (blue) for nuclei. Scale bar = 100 μm. (B) Representative H&E-stained histological sections of major organs (heart, liver, spleen, lungs, and kidneys). Scale bar = 200 μm. (C) Quantitative analysis of microvessel density (MVD) based on CD31-positive areas. (D) Quantitative analysis of CD206-positive areas. (E) Statistical summary of the percentage of F4/80 + CD86 + cells within CD45 + cells in tumor tissues, as determined by flow cytometry. (F) Quantitative analysis of the HIF-1α-positive area percentage in tumor tissues from different groups. REG@LF means REG@LFHA NPs, REG@LFHA means REG@LFHA NPs. All statistical data are represented as mean ± SD (n = 3; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

Article Snippet: Rabbit anti-mouse CD31 polyclonal antibody and rabbit anti-mouse CD206 polyclonal antibody were acquired from Servicebio (Wuhan, China).

Techniques: Immunofluorescence, Staining, Flow Cytometry

Journal: iScience

Article Title: Insufficient erythrocyte-derived S1P: A pathogenic driver and diagnostic biolipid for tumor progression

doi: 10.1016/j.isci.2026.115216

Figure Lengend Snippet: Enhanced tumor growth, immunosuppression, and inhibited angiogenesis in the eSphk1 −/− tumor-bearing mouse model of HNSCC (A) Schematic representation of the experimental strategy used for the mEER tumor-bearing mouse model. (Created with BioRender.com ). (B) Tumor growth profiles of eSphk1 −/− and control mice in the mEER tumor model. ( N = 6 per group, data are presented as mean ± SD. ∗∗ p < 0.01). (C) Representative images of tumors collected from mEER tumor-bearing mice in each group. (D) Tumor weights in mEER tumor-bearing mice of each group. ( N = 6 per group, data are presented as mean ± SD. ∗∗ p < 0.01). (E) RBC SPHK1 activity in different groups at the end of the experiment. ( N = 6 per group, data are presented as mean ± SD. ∗∗ p < 0.01). (F) P50 expression levels in different groups at the end of the experiment. ( N = 6 per group, data are presented as mean ± SD. ∗ p < 0.05). (G) Blood cell counts (RBC, hemoglobin (Hb), WBC and platelets (PLTs)) in different groups at the end of the experiment. Data are presented as mean ± SD ( N = 5 per group, data are presented as mean ± SD). (H) Flow cytometric analysis shows the percentage of immune cells in the tumor tissue of eSphk1 −/− and control mice at the experimental endpoint. ( N = 4:5, data are presented as mean ± SD. ∗ p < 0.05). (I) Representative fluorescent images of immunostaining for CD31, indicating tumor angiogenesis in tumor tissue of eSphk1 −/− and control group mice under mEER tumor-bearing conditions. Green fluorescence indicates CD31 expression on tumor vasculature. ( N = 3 per group, data are presented as mean ± SD. ∗ p < 0.05). (J) The tumor-bearing model in eSphk1 −/− demonstrates that erythrocyte Sphk1 deficiency promotes tumor progression via mechanisms including immune suppression and reduced angiogenesis. (Statistical analysis: Unpaired two-tailed Student’s t test was used for comparisons in panels D–I).

Article Snippet: To assess microvessel density, tumor sections were stained with an anti-CD31 antibody (Proteintech, 28083-1-AP).

Techniques: Control, Activity Assay, Expressing, Immunostaining, Fluorescence, Two Tailed Test

Journal: iScience

Article Title: Insufficient erythrocyte-derived S1P: A pathogenic driver and diagnostic biolipid for tumor progression

doi: 10.1016/j.isci.2026.115216

Figure Lengend Snippet: Mouse breast cancer model validation shows that changes in erythrocyte S1P affect tumor angiogenesis and promote immune suppression, collectively driving tumor progression (A) Schematic representation of the strategy used to establish the orthotopic breast cancer (Py8119) model in mice. (Created with BioRender.com ). (B) Growth profiles of Py8119 tumors in eSphk1 −/− and control mice. ( N = 6 per group, data are presented as mean ± SD. ∗∗∗∗ p < 0.0001). (C) Representative images of tumors collected from Py8119 tumor-bearing mice in each group. ( N = 5 per group). (D) Tumor weights of Py8119 tumor-bearing mice in each group. ( N = 5 per group, data are presented as mean ± SD. ∗∗ p < 0.01). (E) Erythrocyte Sphk1 activities in different experimental groups at the conclusion of the study. ( N = 5 per group, data are presented as mean ± SD. ∗∗ p < 0.01). (F) Flow cytometric analysis shows the percentage of immune cells in tumor tissues of eSphk1 −/− and control mice at the experimental endpoints. ( N = 4 per group, data are presented as mean ± SD. ∗ p < 0.05). (G) Fluorescent immunostaining images of tumor tissue, stained with anti-CD31 to detect tumor angiogenesis. Green fluorescence indicates CD31 expression on tumor vasculature. ( N = 3 per group, data are presented as mean ± SD. ∗∗ p < 0.01).

Article Snippet: To assess microvessel density, tumor sections were stained with an anti-CD31 antibody (Proteintech, 28083-1-AP).

Techniques: Biomarker Discovery, Control, Immunostaining, Staining, Fluorescence, Expressing